United Therapeutics (NASDAQ:UTHR) Upgraded at StockNews.com

StockNews.com upgraded shares of United Therapeutics (NASDAQ:UTHR) from a buy rating to a strong-buy rating in a research note released on Thursday.

Several other equities analysts have also weighed in on the stock. TD Cowen increased their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. The Goldman Sachs Group increased their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. HC Wainwright lifted their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Oppenheimer increased their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Finally, Argus boosted their target price on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $378.36.

United Therapeutics Stock Down 2.0 %

United Therapeutics stock opened at $358.93 on Thursday. United Therapeutics has a 52 week low of $208.62 and a 52 week high of $417.82. The company’s 50 day moving average price is $367.40 and its two-hundred day moving average price is $353.99. The stock has a market cap of $16.03 billion, a P/E ratio of 15.76, a P/E/G ratio of 0.93 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. United Therapeutics’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same period last year, the company posted $5.38 earnings per share. On average, equities analysts anticipate that United Therapeutics will post 25.22 EPS for the current year.

Insider Activity at United Therapeutics

In related news, CFO James Edgemond sold 7,800 shares of United Therapeutics stock in a transaction on Monday, October 28th. The stock was sold at an average price of $350.00, for a total transaction of $2,730,000.00. Following the completion of the sale, the chief financial officer now owns 6,978 shares of the company’s stock, valued at approximately $2,442,300. This trade represents a 52.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Nilda Mesa sold 255 shares of the company’s stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the transaction, the director now owns 5,528 shares in the company, valued at $1,966,696.56. This represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 144,630 shares of company stock valued at $54,371,916. Corporate insiders own 11.90% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of UTHR. USA Financial Formulas bought a new position in shares of United Therapeutics in the 3rd quarter worth $33,000. Brooklyn Investment Group bought a new position in United Therapeutics in the third quarter valued at $33,000. Capital Performance Advisors LLP purchased a new stake in United Therapeutics during the third quarter valued at about $82,000. MassMutual Private Wealth & Trust FSB raised its position in United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 58 shares in the last quarter. Finally, Values First Advisors Inc. bought a new stake in United Therapeutics during the third quarter worth about $90,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.